263 related articles for article (PubMed ID: 23750747)
1. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.
Ryan GM; Kaminskas LM; Kelly BD; Owen DJ; McIntosh MP; Porter CJ
Mol Pharm; 2013 Aug; 10(8):2986-95. PubMed ID: 23750747
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats.
Leong NJ; Mehta D; McLeod VM; Kelly BD; Pathak R; Owen DJ; Porter CJH; Kaminskas LM
J Pharm Sci; 2018 Sep; 107(9):2509-2513. PubMed ID: 29852134
[TBL] [Abstract][Full Text] [Related]
3. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.
Kaminskas LM; McLeod VM; Ryan GM; Kelly BD; Haynes JM; Williamson M; Thienthong N; Owen DJ; Porter CJ
J Control Release; 2014 Jun; 183():18-26. PubMed ID: 24637466
[TBL] [Abstract][Full Text] [Related]
5. Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers.
Haque S; McLeod VM; Jones S; Fung S; Whittaker M; McIntosh M; Pouton C; Owen DJ; Porter CJH; Kaminskas LM
Eur J Pharm Biopharm; 2017 Oct; 119():408-418. PubMed ID: 28713018
[TBL] [Abstract][Full Text] [Related]
6. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep.
Ryan GM; Bischof RJ; Enkhbaatar P; McLeod VM; Chan LJ; Jones SA; Owen DJ; Porter CJ; Kaminskas LM
Pharm Res; 2016 Feb; 33(2):510-25. PubMed ID: 26486513
[TBL] [Abstract][Full Text] [Related]
9. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ
J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.
Kaminskas LM; McLeod VM; Ascher DB; Ryan GM; Jones S; Haynes JM; Trevaskis NL; Chan LJ; Sloan EK; Finnin BA; Williamson M; Velkov T; Williams ED; Kelly BD; Owen DJ; Porter CJ
Mol Pharm; 2015 Feb; 12(2):432-43. PubMed ID: 25485615
[TBL] [Abstract][Full Text] [Related]
11. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
13. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration.
Okuda T; Kawakami S; Maeie T; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Aug; 114(1):69-77. PubMed ID: 16814896
[TBL] [Abstract][Full Text] [Related]
15. Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.
Kaminskas LM; Wu Z; Barlow N; Krippner GY; Boyd BJ; Porter CJ
J Pharm Sci; 2009 Oct; 98(10):3871-5. PubMed ID: 19283758
[TBL] [Abstract][Full Text] [Related]
16. Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.
Zhong Q; Merkel OM; Reineke JJ; da Rocha SR
Mol Pharm; 2016 Jun; 13(6):1866-78. PubMed ID: 27148629
[TBL] [Abstract][Full Text] [Related]
17. Targeting the lymphatics using dendritic polymers (dendrimers).
Kaminskas LM; Porter CJ
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):890-900. PubMed ID: 21683746
[TBL] [Abstract][Full Text] [Related]
18. Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker.
Mehta D; Leong N; McLeod VM; Kelly BD; Pathak R; Owen DJ; Porter CJH; Kaminskas LM
Mol Pharm; 2018 Oct; 15(10):4568-4576. PubMed ID: 30107748
[TBL] [Abstract][Full Text] [Related]
19. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
Boyd BJ; Kaminskas LM; Karellas P; Krippner G; Lessene R; Porter CJ
Mol Pharm; 2006; 3(5):614-27. PubMed ID: 17009860
[TBL] [Abstract][Full Text] [Related]
20. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist.
Gajbhiye V; Vijayaraj Kumar P; Tekade RK; Jain NK
Eur J Med Chem; 2009 Mar; 44(3):1155-66. PubMed ID: 18760863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
